Regarding the systemic difference in SOD activity, some data identifies no difference in plasma SOD activity in patients with pancreatic cancer, suggesting any differences in activity driving tumorigenesis may be local phenomena [39]. This evidence concerns the gene SOD1 and familial pancreatic carcinoma.